tert-butyl (4-(hydroxymethyl)pyridin-2-yl)methylcarbamate | 864460-84-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: tert-butyl (4-(hydroxymethyl)pyridin-2-yl)methylcarbamate
• 英文别名: [2-(N-tert-Butoxycarbonyl-N-methylamino)pyridin-4-yl]methanol；tert-butyl N-[4-(hydroxymethyl)pyridin-2-yl]-N-methylcarbamate
• CAS: 864460-84-4
• 化学式: C₁₂H₁₈N₂O₃
• 分子量: 238.287
• InChiKey: ATHWYVGZFDFSLE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  62.7
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  tert-butyl (4-(hydroxymethyl)pyridin-2-yl)methylcarbamate 在 四溴化碳 、 三苯基膦 作用下， 以 二氯甲烷 为溶剂， 反应 1.33h， 以4.74 g的产率得到tert-butyl (4-(bromomethyl)pyridine-2-yl)methylcarbamate
  参考文献：
  名称：

  THERAPEUTIC COMPOUNDS AND COMPOSITIONS

  摘要：

  本发明提供了抑制XIa因子或激肽酶的化合物和组合物，以及使用这些化合物和组合物的方法。

  公开号：

  US20150225389A1
• 作为产物：
  描述：

  2-(Boc-氨基)异烟酸甲酯 在 锂硼氢 、 sodium hexamethyldisilazane 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 反应 8.25h， 生成 tert-butyl (4-(hydroxymethyl)pyridin-2-yl)methylcarbamate
  参考文献：
  名称：

  THERAPEUTIC COMPOUNDS AND COMPOSITIONS

  摘要：

  本发明提供了抑制XIa因子或激肽酶的化合物和组合物，以及使用这些化合物和组合物的方法。

  公开号：

  US20150225389A1

文献信息

• QUATERNARY LACTAM COMPOUND AND PHARMACEUTICAL USE THEREOF
  申请人：SHANGHAI MEIYUE BIOTECH DEVELOPMENT CO., LTD.

  公开号：US20210032219A1

  公开（公告）日：2021-02-04

  A quaternary lactam compound of formula (I). The compound is used in the manufacture of a medicament for the treatment and/or prevention of thrombotic or thromboembolic disorders.

  化合物的分子式是(I)，是一种四元内酰胺化合物。该化合物用于制造治疗和/或预防血栓性或栓塞性疾病的药物。
• [EN] THERAPEUTIC COMPOUNDS AND COMPOSITIONS<br/>[FR] COMPOSÉS ET COMPOSITIONS THÉRAPEUTIQUES
  申请人：EXITHERA PHARMACEUTICALS INC

  公开号：WO2018118705A1

  公开（公告）日：2018-06-28

  The present invention provides compounds that inhibit Factor XIa or kallikrein and pharmaceutically acceptable salts thereof and compositions thereof. The present invention also provides methods of using these compounds and compositions.

  本发明提供了抑制因子XIa或激肽酶以及其药用盐和组合物的化合物。本发明还提供了使用这些化合物和组合物的方法。
• Novel cyclic compound having 4-pyridylalkylthio group having substituted or unsubstituted amino group introduced therein
  申请人：Honda Takahiro

  公开号：US20070149574A1

  公开（公告）日：2007-06-28

  A novel cyclic compound having a 4-pyridylalkylthio group having an (un)substituted amino group introduced therein or a salt thereof. They are useful as a medicine. The cyclic compound is a compound represented by the following formula (1), which is useful for the treatment of diseases in which angiogenesis participates. In the following formula (1), ring A represents a benzene ring or a 5- or 6-membered aromatic heterocycle optionally fused with a cycloalkane ring; B represents alkylene; R 1 and R 2 each represents H, (substituted) aryl, (substituted) heterocyclic group, etc.; R 3 and R 4 each represents H, (substituted) alkyl, (substituted) cycloalkyl, -Z-R 5 , etc.; R 5 represents (substituted) alkyl, (substituted) aryl, (substituted) heterocyclic group, etc.; X and Y each represents H, etc.; Z represents —CO—, —COO—, —CONR 6 —, —SO 2 —, etc.; R 6 represents H, etc.; p is 0, 1, or 2; and q is 0 or 1.

  一种具有4-吡啶基烷基硫基团的新型环状化合物，其中引入了（未）取代氨基或其盐。它们可用作药物。环状化合物是由以下式（1）表示的化合物，可用于治疗参与血管生成的疾病。在下式（1）中，环A表示苯环或5-或6-成员芳香杂环，可选择地与环烷环融合；B表示烷基；R1和R2各表示H，（取代）芳基，（取代）杂环基等；R3和R4各表示H，（取代）烷基，（取代）环烷基，-Z-R5等；R5表示（取代）烷基，（取代）芳基，（取代）杂环基等；X和Y各表示H等；Z表示-CO-，-COO-，-CONR6-，-SO2-等；R6表示H等；p为0、1或2；q为0或1。
• Cyclic compound having 4-pyridylalkylthio group having substituted or unsubstituted amino group introduced therein
  申请人：Santen Pharmaceutical Co., Ltd.

  公开号：US07544703B2

  公开（公告）日：2009-06-09

  A novel cyclic compound having a 4-pyridylalkylthio group having an (un)substituted amino group introduced therein or a salt thereof. They are useful as a medicine. The cyclic compound is a compound represented by the following formula (1), which is useful for the treatment of diseases in which angiogenesis participates. In the following formula (1), ring A represents a benzene ring or a 5- or 6-membered aromatic heterocycle optionally fused with a cycloalkane ring; B represents alkylene; R1 and R2 each represents H, (substituted) aryl, (substituted) heterocyclic group, etc.; R3 and R4 each represents H, (substituted) alkyl, (substituted) cycloalkyl, -Z-R5, etc.; R5 represents (substituted) alkyl, (substituted) aryl, (substituted) heterocyclic group, etc.; X and Y each represents H, etc.; Z represents —CO—, —COO—, —CONR6—, —SO2—, etc.; R6 represents H, etc.; p is 0, 1, or 2; and q is 0 or 1.

  一种新型环状化合物，具有4-吡啶基烷基硫基团，其中引入了（未）取代氨基或其盐。它们可用作药物。该环状化合物是由以下式（1）表示的化合物，对参与血管生成的疾病的治疗有用。在以下式（1）中，环A表示苯环或可选地与环烷环融合的5或6成员芳香杂环；B表示烷基；R1和R2各表示H，（取代）芳基，（取代）杂环基等；R3和R4各表示H，（取代）烷基，（取代）环烷基，-Z-R5等；R5表示（取代）烷基，（取代）芳基，（取代）杂环基等；X和Y各表示H等；Z表示—CO—，—COO—，—CONR6—，—SO2—等；R6表示H等；p为0、1或2；q为0或1。
• Therapeutic compounds and compositions
  申请人：eXithera Pharmaceuticals, Inc.

  公开号：US10259785B2

  公开（公告）日：2019-04-16

  The present invention provides compounds and compositions that inhibit Factor XIa or kallikrein and methods of using these compounds and composition.

  本发明提供了抑制因子 XIa 或 Kallikrein 的化合物和组合物，以及使用这些化合物和组合物的方法。